Evidence map›Paper›PMID 39273493›Full record

ArticleInternational journal of molecular sciences2024

Ginsenoside Rh

Shujuan Pan, Luyuan Peng, Qion Yi, Weijin Qi, Hui Yang, Hongying Wang, Lu Wang

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Ultra-short cyclic peptide CyZoological research · 2025
    Article
  4. Construction and Characterization of an lpxM-DeficientInfection and drug resistance · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shujuan PanSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Luyuan PengCollege of Veterinary Medicine, Jilin University, Changchun 130062, China.
Qion YiEngineering Research Center of the Utilization for Characteristic Bio-Pharma Ceutical Resources in Southwest, Ministry of Education, Guizhou University, Guiyang 550025, China.
Weijin QiEngineering Research Center of the Utilization for Characteristic Bio-Pharma Ceutical Resources in Southwest, Ministry of Education, Guizhou University, Guiyang 550025, China.
Hui YangEngineering Research Center of the Utilization for Characteristic Bio-Pharma Ceutical Resources in Southwest, Ministry of Education, Guizhou University, Guiyang 550025, China.
Hongying WangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Lu WangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.

Funding

National Natural Science Foundation of China 31760747National Natural Science Foundation of China 32160849National Natural Science Foundation of China 32273051
6 · The paper itself

Abstract

Lipopolysaccharide (LPS) triggers a severe systemic inflammatory reaction in mammals, with the dimerization of TLR

Indexed as

GinsenosidesLipopolysaccharidesLymphocyte Antigen 96Toll-Like Receptor 4AnimalsAnti-Inflammatory AgentsInflammationInterleukin-6MacrophagesMiceMolecular Docking SimulationNitric OxideProtein BindingProtein MultimerizationRAW 264.7 CellsSignal TransductionAnti-Inflammatory Agentsginsenoside Rh2GinsenosidesInterleukin-6LipopolysaccharidesLy96 protein, mouseLymphocyte Antigen 96Nitric OxideTlr4 protein, mouseToll-Like Receptor 4Tumor Necrosis Factor-alphaG-Rh2inflammationtargetTLR4/MD-2TLR4 signaling pathway

Identifiers

PMID39273493
PMCPMC11395244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.